1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
A Time for Patience - 4: Toho University Joins Ionis’ Global Trial for FUS-ALS
Development has now gotten underway in Japan for a new drug targeting ALS caused by FUS gene mutations (FUS-ALS). The compound in question is ION363, an antisense oligonucleotide being developed by US biotech Ionis Pharmaceuticals, which could become the first…
To read the full story
Related Article
- A Time for Patience - 5: Focus Turning to Early and Preclinical ALS Treatment, TDP-43 as New Target
August 28, 2024
- A Time for Patience - 3: As iPSC-Based Drug Discovery Advances, Will 2 Existing Meds Be Repurposed for ALS?
August 26, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- A Time for Patience - 1: New Drugs for ALS Emerging, Some Close to Approval; Can They Meet Unmet Needs?
August 22, 2024
BUSINESS
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- Nxera Founder Tamura to Bow Out from Board
February 17, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…